

Susana Almenara de Riquer

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8435140/susana-almenara-de-riquer-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10
papers

67
citations

5
h-index

7
g-index

13
ext. papers

142
ext. citations

5.4
avg, IF

2.09
L-index

#	Paper	IF	Citations
10	Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates. <i>Biomedicines</i> , 2020 , 8,	4.8	20
9	The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 2051-2062	3.8	8
8	Multimorbidity and psychotropic polypharmacy among participants with autism spectrum disorder with intellectual disability. <i>Psychiatry Research</i> , 2020 , 292, 113321	9.9	8
7	Treatment with non-selective beta-blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis. <i>Liver International</i> , 2018 , 38, 2219-2227	7.9	8
6	Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial. <i>Human Psychopharmacology</i> , 2021 , 36, 1-12	2.3	5
5	Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics. <i>Advances in Therapy</i> , 2021 , 38, 1035-1054	4.1	5
4	Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 133, 111087	7.5	5
3	Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran. <i>Advances in Therapy</i> , 2020 , 37, 3537-3550	4.1	4
2	Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohns Disease. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 1357-1366	4.5	3
1	Functionality of beta-adrenergic receptors in patients with cirrhosis treated chronically with non-selective beta-blockers. <i>Hepatology International</i> , 2020 , 14, 858-868	8.8	1